Janney Montgomery Scott LLC Sells 9,356 Shares of Insulet Corporation $PODD

Janney Montgomery Scott LLC lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 65.2% during the first quarter, Holdings Channel.com reports. The institutional investor owned 5,002 shares of the medical instruments supplier’s stock after selling 9,356 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Insulet were worth $1,050,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares during the period. Geode Capital Management LLC raised its stake in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares during the period. Invesco Ltd. raised its stake in Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares during the period. Norges Bank acquired a new stake in Insulet during the 4th quarter valued at $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Insulet by 3.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after purchasing an additional 29,690 shares during the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of several research reports. Truist Financial decreased their price objective on shares of Insulet from $250.00 to $219.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet in a report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 target price for the company. UBS Group set a $219.00 price target on shares of Insulet in a research note on Thursday, June 11th. Evercore set a $180.00 price objective on shares of Insulet in a research report on Monday, July 6th. Finally, Bank of America decreased their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $237.08.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of Insulet stock opened at $161.28 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The firm has a 50-day moving average of $152.93 and a 200-day moving average of $210.77. Insulet Corporation has a 52-week low of $138.79 and a 52-week high of $354.88. The stock has a market cap of $11.17 billion, a PE ratio of 37.51, a PEG ratio of 1.12 and a beta of 1.11.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period last year, the firm earned $1.02 earnings per share. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Stifel kept a buy rating on PODD, although it lowered its price target from $250 to $225, suggesting the stock still has meaningful upside despite recent volatility. Benzinga reference
• Neutral Sentiment: Insulet also appeared in a positive-style growth note and an article discussing the stock’s valuation after a sharp decline, but these pieces did not provide fresh company-specific catalysts. Yahoo Finance reference
• Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not currently signal a meaningful bearish positioning change.
• Negative Sentiment: Several law firms announced or promoted class-action lawsuits against Insulet over alleged securities fraud and Omnipod safety disclosures, which can create investor uncertainty and pressure the stock. PR Newswire reference

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.